CareDx PE Ratio 2013-2025 | CDNA
Current and historical p/e ratio for CareDx (CDNA) from 2013 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. CareDx PE ratio as of June 13, 2025 is 16.17.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| CareDx PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-13 | 18.59 | 16.17 | |
| 2025-03-31 | 17.75 | $1.15 | 15.43 |
| 2024-12-31 | 21.41 | $1.02 | 20.99 |
| 2024-09-30 | 31.23 | $-2.70 | 0.00 |
| 2024-06-30 | 15.53 | $-2.99 | 0.00 |
| 2024-03-31 | 10.59 | $-3.42 | 0.00 |
| 2023-12-31 | 12.00 | $-3.54 | 0.00 |
| 2023-09-30 | 7.00 | $-1.67 | 0.00 |
| 2023-06-30 | 8.50 | $-1.56 | 0.00 |
| 2023-03-31 | 9.14 | $-1.51 | 0.00 |
| 2022-12-31 | 11.41 | $-1.44 | 0.00 |
| 2022-09-30 | 17.02 | $-1.41 | 0.00 |
| 2022-06-30 | 21.48 | $-1.32 | 0.00 |
| 2022-03-31 | 36.99 | $-0.95 | 0.00 |
| 2021-12-31 | 45.48 | $-0.59 | 0.00 |
| 2021-09-30 | 63.37 | $-0.35 | 0.00 |
| 2021-06-30 | 91.52 | $-0.18 | 0.00 |
| 2021-03-31 | 68.09 | $-0.29 | 0.00 |
| 2020-12-31 | 72.45 | $-0.42 | 0.00 |
| 2020-09-30 | 37.94 | $-0.46 | 0.00 |
| 2020-06-30 | 35.43 | $-0.44 | 0.00 |
| 2020-03-31 | 21.83 | $-0.48 | 0.00 |
| 2019-12-31 | 21.57 | $-0.52 | 0.00 |
| 2019-09-30 | 22.61 | $-0.50 | 0.00 |
| 2019-06-30 | 35.99 | $-1.00 | 0.00 |
| 2019-03-31 | 31.52 | $-1.21 | 0.00 |
| 2018-12-31 | 25.14 | $-1.33 | 0.00 |
| 2018-09-30 | 28.85 | $-2.37 | 0.00 |
| 2018-06-30 | 12.24 | $-2.46 | 0.00 |
| 2018-03-31 | 7.97 | $-2.25 | 0.00 |
| 2017-12-31 | 7.34 | $-2.21 | 0.00 |
| 2017-09-30 | 3.70 | $-1.81 | 0.00 |
| 2017-06-30 | 1.11 | $-1.44 | 0.00 |
| 2017-03-31 | 1.40 | $-2.01 | 0.00 |
| 2016-12-31 | 2.70 | $-2.56 | 0.00 |
| 2016-09-30 | 3.55 | $-2.23 | 0.00 |
| 2016-06-30 | 4.31 | $-2.26 | 0.00 |
| 2016-03-31 | 4.96 | $-1.77 | 0.00 |
| 2015-12-31 | 6.40 | $-1.15 | 0.00 |
| 2015-09-30 | 4.17 | $-0.75 | 0.00 |
| 2015-06-30 | 6.50 | $-0.34 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.035B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.613B | 26.94 |
| Elevance Health (ELV) | United States | $86.883B | 11.21 |
| CVS Health (CVS) | United States | $85.338B | 10.61 |
| Cencora (COR) | United States | $57.283B | 19.93 |
| DiDi Global (DIDIY) | China | $22.826B | 24.25 |
| Natera (NTRA) | United States | $22.577B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.856B | 17.73 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.669B | 0.00 |
| Solventum (SOLV) | United States | $12.768B | 13.52 |
| ICON (ICLR) | Ireland | $11.763B | 10.94 |
| CochLear (CHEOY) | Australia | $11.550B | 0.00 |
| Revvity (RVTY) | United States | $11.024B | 18.97 |
| Doximity (DOCS) | United States | $10.503B | 48.63 |
| Viatris (VTRS) | United States | $10.469B | 3.60 |
| HealthEquity (HQY) | United States | $9.059B | 39.68 |
| Avantor (AVTR) | United States | $8.906B | 12.94 |
| Medpace Holdings (MEDP) | United States | $8.572B | 22.77 |
| Sonic Healthcare (SKHHY) | Australia | $8.393B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.340B | 14.38 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.361B | 25.69 |
| BrightSpring Health Services (BTSG) | United States | $3.724B | 34.16 |
| Sotera Health (SHC) | United States | $3.244B | 18.43 |
| Alignment Healthcare (ALHC) | United States | $2.956B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.914B | 37.90 |
| Concentras Parent (CON) | United States | $2.749B | 15.89 |
| Organon (OGN) | United States | $2.610B | 2.77 |
| Ardent Health (ARDT) | United States | $1.881B | 8.02 |
| Premier (PINC) | United States | $1.858B | 14.11 |
| GeneDx Holdings (WGS) | United States | $1.842B | 70.96 |
| Progyny (PGNY) | United States | $1.803B | 39.68 |
| PACS (PACS) | United States | $1.573B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.561B | 31.21 |
| Teladoc Health (TDOC) | United States | $1.203B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.203B | 9.15 |
| Establishment Labs Holdings (ESTA) | $1.083B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.890B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.826B | 7.73 |
| QDM (QDMI) | Hong Kong, SAR China | $0.763B | 0.00 |
| Nutex Health (NUTX) | United States | $0.679B | 10.28 |
| LifeMD (LFMD) | United States | $0.566B | 0.00 |
| Embecta (EMBC) | United States | $0.559B | 3.76 |
| Enhabit (EHAB) | United States | $0.495B | 40.75 |
| InnovAge Holding (INNV) | United States | $0.478B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.467B | 10.52 |
| SBC Medicals (SBC) | United States | $0.459B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.453B | 0.00 |
| Omada Health (OMDA) | $0.440B | 0.00 | |
| COMPASS Pathways (CMPS) | United Kingdom | $0.411B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.255B | 0.00 |
| Oncology Institute (TOI) | United States | $0.220B | 0.00 |
| Beauty Health (SKIN) | United States | $0.193B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.148B | 24.17 |
| Pheton Holdings (PTHL) | China | $0.114B | 0.00 |
| So-Young (SY) | China | $0.097B | 0.00 |
| KindlyMD (NAKA) | United States | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.076B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.064B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.064B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| Biodesix (BDSX) | United States | $0.042B | 0.00 |
| ModivCare (MODV) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.028B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |